Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE